Literature DB >> 10443879

Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation.

C S Raine1, B Cannella, S L Hauser, C P Genain.   

Abstract

Neuropathological and ultrastructural features of central nervous system demyelination were compared in marmoset experimental autoimmune encephalomyelitis (EAE) induced with myelin/oligodendrocyte glycoprotein (MOG), and in 3 cases of multiple sclerosis (MS) displaying recent lesions. At the edges of EAE and MS lesions, a zone of myelin vacuolation was common, whereas in the lesion proper, myelin sheaths were consistently transformed into vesiculated membranous networks. These networks became dissociated from axons by cell processes from macrophages. Oligodendrocytes were remarkably spared and evidence of myelin repair was present but not prominent. Axonal pathology was more common in the MS material than in marmoset EAE. Immunocytochemistry, using gold-labeled encephalitogenic peptides of MOG and silver enhancement to detect MOG autoantibodies, revealed the presence of MOG-specific autoantibodies over vesiculated myelin networks. Gold-labeled antibody to IgG also gave a positive reaction. Gold-labeled peptide of myelin basic protein did not react with MOG/EAE tissue, but the same conjugate gave positive staining in MS (and in marmoset EAE induced by whole white matter), perhaps indicating broader spectrum immunoreactivity or sensitization to myelin antigens. Thus, vesicular disruption of myelin was a constant feature in these evolving, highly active lesions in primate EAE and MS and appeared causally related to the deposition of antigen-specific autoantibodies.

Entities:  

Mesh:

Year:  1999        PMID: 10443879     DOI: 10.1002/1531-8249(199908)46:2<144::aid-ana3>3.0.co;2-k

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  47 in total

Review 1.  Role of HLA class II genes in susceptibility and resistance to multiple sclerosis: studies using HLA transgenic mice.

Authors:  David Luckey; Dikshya Bastakoty; Ashutosh K Mangalam
Journal:  J Autoimmun       Date:  2011-05-31       Impact factor: 7.094

Review 2.  Multiple sclerosis.

Authors:  Alyssa Nylander; David A Hafler
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 3.  Humoral immunity in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.

Authors:  Anne H Cross; Jennifer L Stark
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

Review 4.  Myelin architecture: zippering membranes tightly together.

Authors:  Mostafa Bakhti; Shweta Aggarwal; Mikael Simons
Journal:  Cell Mol Life Sci       Date:  2013-10-29       Impact factor: 9.261

Review 5.  B cells in multiple sclerosis: connecting the dots.

Authors:  H-Christian von Büdingen; Amit Bar-Or; Scott S Zamvil
Journal:  Curr Opin Immunol       Date:  2011-10-07       Impact factor: 7.486

Review 6.  Concepts of myelin and myelination in neuroradiology.

Authors:  A J Barkovich
Journal:  AJNR Am J Neuroradiol       Date:  2000 Jun-Jul       Impact factor: 3.825

7.  Virus-specific antibody, in the absence of T cells, mediates demyelination in mice infected with a neurotropic coronavirus.

Authors:  Taeg S Kim; Stanley Perlman
Journal:  Am J Pathol       Date:  2005-03       Impact factor: 4.307

Review 8.  The Charcot Lecture | beating MS: a story of B cells, with twists and turns.

Authors:  Stephen L Hauser
Journal:  Mult Scler       Date:  2014-12-05       Impact factor: 6.312

9.  B cells produce pathogenic antibodies and impair recovery after spinal cord injury in mice.

Authors:  Daniel P Ankeny; Zhen Guan; Phillip G Popovich
Journal:  J Clin Invest       Date:  2009-09-21       Impact factor: 14.808

Review 10.  [Targeting B cells in multiple sclerosis. Current concepts and strategies].

Authors:  T Menge; H-C Büdingen; M C Dalakas; B C Kieseier; H-P Hartung
Journal:  Nervenarzt       Date:  2009-02       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.